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OBJECTIVE — Toassessthepredictivevalueofthemetabolicsyndromeinpatientswithtype
1 diabetes.
RESEARCH DESIGN AND METHODS — Patients were from the prospective Finnish
Diabetic Nephropathy (FinnDiane) Study (n  3,783): mean age 37  12 years and diabetes
duration 23  12 years. Metabolic syndrome was deﬁned according to World Health Organi-
zation (WHO), National Cholesterol Education Program (NCEP), and International Diabetes
Federation (IDF) deﬁnitions. Follow-up time was median 5.5 years (interquartile range 3.7–
6.7).Mortalitydatawerecomplete,whereasmorbiditydatawereavailablein69%ofthepatients.
RESULTS — The WHO deﬁnition was associated with a 2.1-fold increased risk of cardiovas-
cular events and a 2.5-fold increased risk of cardiovascular- and diabetes-related mortality, after
adjustment for traditional risk factors and diabetic nephropathy. The NCEP deﬁnition did not
predictoutcomeswhenadjustedfornephropathybutmarkedlyaddedtotheriskassociatedwith
elevated albuminuria alone (P  0.001). The IDF deﬁnition did not predict outcomes.
CONCLUSIONS — The metabolic syndrome is a risk factor, beyond albuminuria, for car-
diovascular morbidity and diabetes-related mortality in type 1 diabetes.
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T
ype 1 diabetes is associated with an
increased risk of cardiovascular
morbidity and mortality, which is
largely, but not totally, explained by the
presenceofdiabeticnephropathy(1).The
metabolic syndrome, a cluster of cardio-
vascular risk factors, increases the risk of
cardiovascular disease and chronic renal
disease in the general population and in
patients with type 2 diabetes (2–4). The
metabolic syndrome is common in pa-
tients with type 1 diabetes (5–7), but its
role as a predictor of cardiovascular dis-
easeanddiabeticnephropathyislessclear
(8,9).Therefore,theaimofthisstudywas
to assess the predictive value of the differ-
entdeﬁnitionsofthemetabolicsyndrome
for cardiovascular events, cardiovascular-
and diabetes-related mortality, and the
progression of renal disease in type 1
diabetes.
RESEARCH DESIGN AND
METHODS— All patients partici-
pated in the Finnish Diabetic Nephropa-
thy (FinnDiane) Study, initiated in 1997.
The present study is prospective and in-
cludes 3,783 adult patients with type 1
diabetes from the FinnDiane Study, who
at baseline had complete lipid proﬁles
and data available on the components of
the metabolic syndrome. A more detailed
description of the baseline visit has previ-
ously been reported (5). Of the patients,
2,270 had a normal urinary albumin ex-
cretion rate (UAER), 477 microalbumin-
uria, 543 macroalbuminuria, and 241
end-stage renal disease (ESRD). Diabetic
nephropathy was deﬁned as macroalbu-
minuria or ESRD. In 252 patients, renal
status could not be assessed. The meta-
bolicsyndromewasassessedaccordingto
World Health Organization (MS
WHO)
(10), National Cholesterol Education
Program (MS
NCEP) (11), and Interna-
tional Diabetes Federation (MS
IDF) (12)
deﬁnitions (see supplementary Table A1,
available in the online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-2022/DC1). All patients with
type 1 diabetes fulﬁlled the criteria for
hyperglycemia.
Data on mortality were available for
allpatients,anddeathcertiﬁcateswerere-
trieved from Statistics Finland. Cardio-
vascular- and diabetes-related mortality
was used as the end point, deﬁned as un-
derlying or immediate cardiovascular- or
diabetes-related cause of death. Collec-
tionoffollow-updataonmorbidityisstill
ongoing; data on cardiovascular morbid-
ity were available for 2,474 patients
(65%) and data on progression of renal
diseasefor2,594patients(69%).Thedata
were collected from follow-up visits
(36%)ormedicalﬁles(64%).Progression
ofrenaldiseasewasdeﬁnedasachangein
category from normal UAER to mi-
croalbuminuria (n  118), microalbu-
minuria to macroalbuminuria (n  54),
or macroalbuminuria to ESRD (n  130).
RESULTS— At baseline, the preva-
lence of MS
WHO was 44%, MS
NCEP 35%,
and MS
IDF 36%. The overlap of the three
deﬁnitions is shown in Figure A1 in the
onlineappendix.Detailedclinicalcharac-
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Table A2 in the online appendix.
During median 5.5 years (interquar-
tile range 3.7–6.7) of follow-up, 263 pa-
tients suffered a cardiovascular event; of
these, 106 had a history of previous
events and 173 had diabetic nephropathy
at baseline. The predictive value of
MS
WHO,M S
NCEP, and MS
IDF for out-
comes is shown in Table 1. Of individual
metabolic syndrome components, all ex-
cept obesity were independent predictors
of a new cardiovascular event, adjusted
for the traditional risk factors: MS
WHO el-
evated UAER (HR 2.69 [95% CI 1.95–
3.72]), MS
WHO hypertension (1.71
[1.26–2.31]),MS
WHOdyslipidemia(1.80
[1.38–2.35]), MS
NCEP hypertension
(2.00 [1.36–2.93]), MS
NCEP low HDL
cholesterol (1.35 [1.03–1.78]), MS
NCEP
high triglycerides (1.83 [1.35–2.48]),
MS
IDF hypertension (4.25 [2.28–7.92]),
MS
IDF low HDL cholesterol (1.63 [1.24–
2.13]), MS
IDF high triglycerides (1.76
[1.31–2.37]), MS
WHO obesity (1.28
[0.97–1.68]), MS
NCEP obesity (0.94
[0.68–1.30]), and MS
IDF obesity (0.82
[0.63–1.06]).
MS
NCEP added to the risk attributed
to elevated UAER for cardiovascular
events(P0.001).Inthosewithelevated
UAER,MS
NCEPwasassociatedwithanHR
of 1.44 (95% CI 1.06–1.96) for a new
cardiovascular event, after adjustment for
traditional risk factors and diabetic ne-
phropathy (see Figure A2 in the online
appendix).
Duringamedian5.7years(interquar-
tile range 4.0–6.9) of follow-up, 238 pa-
tients died from either cardiovascular- or
diabetes-related causes. The predictive
value of the metabolic syndrome on car-
diovascular- and diabetes-related mortal-
ity is shown in Table 1. Of individual
components of the metabolic syndrome,
all except obesity were independent pre-
dictors of cardiovascular- and diabetes-
related mortality. The predictive value
of the metabolic syndrome on the pro-
gression of diabetic nephropathy is
shown in Table 1. The protective role of
MS
IDF was largely due to MS
IDF obesity
(HR 0.39 [95% CI 0.26–0.57]), which
was the only component that was seem-
ingly protective.
CONCLUSIONS— Our main ﬁnd-
ings support data from two prospective
studies on the role of the metabolic syn-
drome in type 1 diabetes (8,9). Of the
current deﬁnitions, MS
WHO is associated
with the highest risk of cardiovascular
outcomes, followed by MS
NCEP, whereas
MS
IDF is the weakest predictor.
Diabetic nephropathy is accompa-
niedbythemetabolicsyndrome(5)andis
alsothestrongestriskfactorforcardiovas-
cular outcomes in patients with type 1
diabetes.Inthepresentstudy,mostofthe
cardiovascular events were seen in those
with diabetic nephropathy. Taking these
facts into consideration, it is difﬁcult to
eliminatediabeticnephropathywherethe
role of the metabolic syndrome is as-
sessed. The independent risk shown for
MS
WHOoncardiovasculareventsandcar-
diovascular- and diabetes-related mortal-
ity, adjusted for diabetic nephropathy,
suggests that the metabolic syndrome
plays an independent role. It could, how-
ever,bearguedthattheeffectisduetothe
inclusion of microalbuminuria in the
MS
WHO. We were, however, also able to
show an additional effect of MS
NCEP be-
yond elevated UAER alone, suggesting a
true role of the metabolic syndrome as a
risk factor for cardiovascular outcomes.
The results from the present and earlier
studies suggest that the role of the meta-
bolic syndrome on progression to mi-
croalbuminuria is modest, whereas at
later stages the metabolic syndrome plays
a larger role.
Of the individual components, ab-
dominal obesity seems to play the weak-
est role. This is surprising because
abdominal obesity is a key feature of in-
sulin resistance, an established risk factor
for cardiovascular disease (13). However,
Table 1—Hazard ratios for outcomes by different deﬁnitions of the metabolic syndrome
n MS
WHO P MS
NCEP P MS
IDF P
New cardiovascular event 263 5.73 (4.14–7.92) 0.001 2.45 (1.92–3.14) 0.001 1.66 (1.30–2.11) 0.001
Adjusted for traditional risk factors* 3.65 (2.59–5.14) 0.001 1.89 (1.46–2.46) 0.001 1.09 (0.84–1.41) 0.535
Further adjusted for previous cardiovascular
event 2.98 (2.10–4.24) 0.001 1.64 (1.23–2.14) 0.001 1.03 (0.79–1.33) 0.833
Further adjusted for diabetic nephropathy 2.05 (1.38–3.04) 0.001 1.31 (0.99–1.72) 0.056 0.96 (0.74–1.25) 0.759
New myocardial infarction 161 10.29 (6.14–17.25) 0.001 2.61 (1.90–3.59) 0.001 1.76 (1.29–2.39) 0.001
Adjusted for traditional risk factors* 6.30 (3.68–10.78) 0.001 1.85 (1.32–2.59) 0.001 1.16 (0.83–1.62) 0.375
Further adjusted for previous myocardial
infarction 5.80 (3.38–9.97) 0.001 1.67 (1.19–2.35) 0.003 1.11 (0.79–1.54) 0.558
Further adjusted for diabetic nephropathy 3.10 (1.70–5.68) 0.001 1.17 (0.83–1.65) 0.380 1.00 (0.72–1.40) 0.992
New stroke 80 7.51 (3.86–14.60) 0.001 1.94 (1.25–3.02) 0.003 1.10 (0.70–1.73) 0.684
Adjusted for traditional risk factors* 4.86 (2.42–9.77) 0.001 1.51 (0.94–2.44) 0.090 0.73 (0.45–1.20) 0.218
Further adjusted for previous stroke 4.49 (2.22–9.07) 0.001 1.45 (0.89–2.34) 0.133 0.65 (0.40–1.08) 0.096
Further adjusted for diabetic nephropathy 2.81 (1.29–6.15) 0.010 1.05 (0.64–1.71) 0.859 0.66 (0.40–1.07) 0.093
Cardiovascular- and diabetes-related mortality 238 11.05 (7.25–16.85) 0.001 2.87 (2.21–3.73) 0.001 1.79 (1.39–2.31) 0.001
Adjusted for traditional risk factors* 7.33 (4.69–11.46) 0.001 2.15 (1.63–2.84) 0.001 1.20 (0.92–1.58) 0.185
Further adjusted for diabetic nephropathy 2.52 (1.53–4.16) 0.001 1.31 (0.99–1.73) 0.063 1.00 (0.76–1.32) 0.986
Progression
Normal UAER to microalbuminuria† 118 2.10 (1.42–3.12) 0.001 1.13 (0.77–1.68) 0.531 1.30 (0.88–1.92) 0.191
Micro- to macroalbuminuria† 54 2.42 (0.96–6.12) 0.062 1.57 (0.91–2.71) 0.102 1.65 (0.93–2.92) 0.085
Macroalbuminuria to ESRD† 130 2.57 (1.13–5.86) 0.025 1.65 (1.13–2.40) 0.009 0.52 (0.36–0.75) 0.001
Data are HR (95% CI), derived from Cox regression analyses. *Adjusted for age, sex, smoking, LDL cholesterol, and A1C. †Adjusted for duration of diabetes, sex,
smoking, and A1C.
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independent predictors of both cardio-
vascular events and cardiovascular- and
diabetes-related mortality. In patients on
dialysis, obesity has been associated with
better survival (the obesity paradox),
highlighting the importance of optimal
nutrition (14). In the present study,
MS
IDFobesitywasseeminglyprotectiveof
progression to ESRD, suggesting an in-
verseorU-shapedrelationshipinpatients
with macroalbuminuria.
A major limitation was the incom-
plete follow-up data on mortality, which
was due to the ongoing nature of the
FinnDiane Study. In conclusion, the met-
abolic syndrome is an independent risk
factor for cardiovascular events and adds
to the risk related to albuminuria.
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